Small Pharma Valuation

Is XC6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XC6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XC6's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XC6's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XC6?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for XC6. This is calculated by dividing XC6's market cap by their current preferred multiple.
What is XC6's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CA$50.37m

XC6 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does XC6's PB Ratio compare to its peers?

The above table shows the PB ratio for XC6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.5x
SBX SynBiotic	1.9x	107.0%	€30.5m
APPH Apontis Pharma	1.7x	77.1%	€53.8m
HIGH Cantourage Group	1.4x	89.5%	€63.0m
B8FK Biofrontera	1x	n/a	€17.4m
XC6 Small Pharma	6.3x	n/a	€50.4m

Price-To-Book vs Peers: XC6 is expensive based on its Price-To-Book Ratio (6.3x) compared to the peer average (1x).

Price to Earnings Ratio vs Industry

How does XC6's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.9%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: XC6 is expensive based on its Price-To-Book Ratio (6.3x) compared to the European Pharmaceuticals industry average (2x).

Price to Book Ratio vs Fair Ratio

What is XC6's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XC6 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	6.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XC6's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.